Name | Probenecid |
Synonyms | benacen Benemid Apurina Benuryl benemide colbenemid Probenecid col-probenecid 4-(dipropylsulfamoyl)benzoate 4-(dipropylsulfamoyl)benzoicacid 4-(Dipropylsulfamoyl)benzoic acid Benzoic acid, p-(dipropylsulfamoyl)- 4-((dipropylamino)sulfonyl)-benzoicaci 4-[(dipropylamino)sulfonyl]-benzoicaci 4-[(Dipropylamino)sulfonyl]benzoic acid benzoicacid,4-((dipropylamino)sulfonyl) 4-[(dipropylamino)sulphonyl]benzoic acid Benzoic acid, 4-[(dipropylamino)sulfonyl]- |
CAS | 57-66-9 |
EINECS | 200-344-3 |
InChI | InChI=1/C13H19NO4S/c1-3-9-14(10-4-2)19(17,18)12-7-5-11(6-8-12)13(15)16/h5-8H,3-4,9-10H2,1-2H3,(H,15,16)/p-1 |
Molecular Formula | C13H19NO4S |
Molar Mass | 285.36 |
Density | 1.2483 (rough estimate) |
Melting Point | 194-196°C |
Boling Point | 438.0±47.0 °C(Predicted) |
Flash Point | 218.7°C |
Water Solubility | <0.1 g/100 mL at 20 ºC |
Solubility | Dissolved in acetone, slightly dissolved in ethanol or chloroform, almost insoluble in water; dissolved in dilute sodium hydroxide solution, almost insoluble in dilute acid. |
Vapor Presure | 1.91E-08mmHg at 25°C |
Appearance | White crystalline powder |
Color | White to Off-White |
Merck | 14,7754 |
pKa | 5.8(at 25℃) |
Storage Condition | Store at RT |
Stability | Stable, but may be light sensitive. Incompatible with strong oxidizing agents. |
Refractive Index | 1.6800 (estimate) |
MDL | MFCD00038402 |
Physical and Chemical Properties | White crystalline powder. Melting point 194-196 °c. Soluble in acetone, slightly soluble in ethanol or chloroform, almost insoluble in water. Soluble in dilute sodium hydroxide solution, almost insoluble in dilute acid. No odor, slightly bitter taste. |
Use | For the treatment of gout, chronic rheumatoid arthritis and other diseases |
Hazard Symbols | Xn - Harmful |
Risk Codes | R22 - Harmful if swallowed R40 - Limited evidence of a carcinogenic effect |
Safety Description | S36/37 - Wear suitable protective clothing and gloves. S24/25 - Avoid contact with skin and eyes. |
UN IDs | 3249 |
WGK Germany | 3 |
RTECS | DG9400000 |
TSCA | Yes |
HS Code | 29350090 |
Raw Materials | Sodium bromide |
Reference Show more | 1. [IF=1.627] Yanming Xia et al."Transport mechanism of ursodeoxycholic acid in human placental BeWo cells."Biopharm Drug Dispos. 2018 Jul;39(7):335-343 |
This product is p-[(dipropylamino) sulfonyl] benzoic acid. The content of C13H19N04S shall be between 98.0% and 102.0% calculated as dry.
The melting point of this product (General 0612) is 198~201°C.
take 2.0g of this product, add 100ml of fresh boiling cold water, heat it on a water bath for 5 minutes, shake it constantly, let it cool and filter it; Take 50ml of filtrate, add several drops of phenolphthalein indicator solution, with sodium hydroxide titration solution (0.lmol/L) titration, consumption of sodium hydroxide titration solution (0.lmol/L) not over 0.25.
take 1.6g of this product, add 0801 ml of water and 1 ml of nitric acid, heat it on a water bath for 5 minutes, shake it constantly, let it cool and filter it; Take 25ml of filtrate and check it according to law (general rule), with standard sodium chloride solution 7.0ml of the control solution should not be more concentrated (0.018%).
take 25ml of the filtrate remaining under the above chloride check item and check it according to law (General rule 0802). Compared with the control solution made of 0.025% of standard potassium sulfate solution, it should not be more concentrated ().
take an appropriate amount of this product, add the mobile phase to dissolve and quantitatively dilute to prepare a solution containing 60ug in μl ml as a test solution; Take lml for precision measurement and put it in a 100ml measuring flask, dilute to the scale with the mobile phase, shake, and serve as a control solution. According to the chromatographic conditions under the content determination item, 20 u1 of each of the control solution and the test solution are accurately measured and injected into the human liquid chromatograph respectively, and the chromatogram is recorded to 5 times of the retention time of the main component peak. If there are impurity peaks in the chromatogram of the test solution, the area of a single impurity peak shall not be greater than 0.5 times (0.5%) of the area of the main peak of the control solution, the sum of each impurity peak area shall not be greater than 2 times (2.0%) of the main peak area of the control solution.
take this product, dry to constant weight at 105°C, weight loss shall not exceed 0.5% (General rule 0831).
not more than 0.1% (General rule 0841).
take l.Og of this product, Add 10ml of sodium hydroxide solution to dissolve, add water to make 25ml, check according to law (General rule 0821 third method), containing heavy metals shall not exceed 10 parts per million.
measured by high performance liquid chromatography (General 0512).
silica gel bonded with octa-alkyl silane was used as the filler, and 0.05mol/L sodium dihydrogen phosphate (1% glacial acetic acid was added, pH was adjusted to 3.0 with phosphoric acid)-acetonitrile (50:50) was used as the mobile phase; the detection wavelength was 245mn. The number of theoretical plates shall not be less than 3000 based on the calculation of probenecid peak.
take an appropriate amount of this product, precisely weigh it, add mobile phase to dissolve and quantitatively dilute to prepare a solution containing 60ug per lml, take 20 u1 for precise measurement, inject human liquid chromatograph, record chromatogram; another reference substance of Probenecid was taken and determined by the same method. According to the external standard method to calculate the peak area, that is.
anti-gout drugs.
light shielding, sealed storage.
This product contains probenecid (C13H19N04S) should be 95.0% to 105.0% of the label.
This product is white tablet.
Take 10 tablets of this product, precision weighing, fine grinding, precision weighing take appropriate amount (about 60mg equivalent to probenecid), 200ml flask, add 150ml ethanol and hydrochloric acid solution (9-100)4ml, heat on 70°C water bath for 30 minutes, let it cool, dilute to the scale with ethanol, shake well, filter, Take 5ml of continued filtrate accurately, put it in a 100ml measuring flask, add hydrochloric acid solution (9-100)2ml, dilute with ethanol to the scale, shake, UV-visible spectrophotometry (General 0401), at the wavelength of 249nm absorbance, calculated as the absorption coefficient of C13H19N04S is 338.
The same as probenecid.
0.25g
light shielding, sealed storage.
NIST chemical information | information provided by: webbook.nist.gov (external link) |
EPA chemical substance information | information provided by: ofmpeb.epa.gov (external link) |
anti-gout drug | Probenecid is a chemically synthesized sulfonamide anti-gout drug, it has the dual function of promoting uric acid excretion and inhibiting penicillin excretion. It is clinically used for chronic gout and inhibiting the excretion of penicillin drugs to increase their plasma concentration, and is used as an auxiliary drug for penicillin treatment. Its mechanism of action is to inhibit the renal tubular reabsorption of uric acid, increase uric acid excretion, thereby reducing the concentration of uric acid in the plasma, to reduce the deposition of urate in the tissue, to prevent the formation of urate crystals. This product can also promote the formation of uric acid salt dissolution, thereby reducing joint damage. In addition, this product can also competitively inhibit the secretion of weak organic acids (such as penicillin, cephalosporin) in renal tubules, which can increase the blood concentration of these antibiotics and prolong their action time. This product is easy to be absorbed by oral administration, and the plasma protein binding rate is as high as 85% ~ 90%. Adults each oral 1G, 2~4 hours blood drug concentration peak, half-life of 6~12 hours. Probenecid is rapidly metabolized in the liver, and the main metabolite is acetylglucuronic acid. Metabolites are mainly excreted in the urine. This product has no anti-inflammatory and analgesic effect, so it is invalid for acute gout. Acute toxicity test results: Rat oral LD50 1600mg/kg. After taking the main adverse reactions are gastrointestinal reactions, other may have dizziness, Head Pain, facial flushing, frequent urination, gingival swelling and pain, rash; Occasionally see allergic reactions. Acute gout attack and renal ureter uric acid crystal deposition history should not be applied. Peptic ulcer or abnormal blood system, pregnant women with caution. It is contraindicated in patients with renal dysfunction. |
indication | (1) hyperuricemia with chronic gouty arthritis and tophi, 25 mg bid for adults, after 1 week can be increased to 2 times a day, each time 500 mg. When taking medicine, the patient takes about 2500mL of water daily to prevent the formation of kidney stones. But must: 1, glomerular filtration greater than 50 ~ 60mL/min;2, no history of kidney stones or kidney stones; 3, non-acidic urine; 4, not taking salicylic acid drugs; 5, regular detection of blood and urine pH, liver and kidney function and blood and urine uric acid levels; 6, according to the clinical and uric acid levels to adjust the dose, with the minimum effective amount to maintain a long time. (2) as an adjunct to antibiotic therapy, when used with antibiotics such as penicillin, ampicillin, oxacillin, O-cloxacillin and nafcillin, probenecid can inhibit the excretion of these antibiotics, increase the blood concentration and can be maintained for a long time. |
adverse reactions | 1. Gastrointestinal reaction: mainly for a small number of patients with loss of appetite, Nausea, Vomit, abdominal discomfort. 2. Central nervous reaction and allergic reaction: Head Pain, facial flushing, Fever, skin itching, dermatitis and other allergic reactions were found occasionally. 3. Other serious toxic reactions: very few patients had hemorrhage, neutropenia, aplastic anemia, nephrotic syndrome, liver necrosis, etc. Probenecid is a sulfa drug, so it is contraindicated in patients with sulfa drug allergy. Pregnant women, peptic ulcer, liver and kidney dysfunction patients should be used with caution. In addition, medication should be a lot of water, and take the right amount of sodium carbonate to prevent urinary stones. During the medication should pay attention to check the blood. |
Use | anti-gout drug. The product is an organic acid, fat-soluble strong, from the tubular secretion of discharge, but also easy to be back to absorption. Therefore, in the presence of propane sulfonic acid, the operation of some organic acids in the renal tubules will be inhibited, and the excretion of other organic acids will be reduced. Therefore, for the treatment of chronic gout, safe and effective. It has no effect on pain and inflammation of acute gout and is not suitable for acute gout. for the treatment of gout, chronic rheumatoid arthritis and other diseases |
production method | p-toluenesulfonamide is oxidized by sodium dichromate to p-carboxybenzenesulfonamide, and then subjected to alkylation reaction with bromopropane, the obtained sodium Probenecid was acidified with acetic acid to obtain probenecid. |
toxic substance data | information provided by: pubchem.ncbi.nlm.nih.gov (external link) |